Skip to main content
Brian Rini, MD, Oncology, Nashville, TN, Vanderbilt University Medical Center

BrianIRiniMDFASCO

Oncology Nashville, TN

Genitourinary Oncology, Hematologic Oncology

Brian Rini, MD, FASCO Professor of Medicine Chief of Clinical Trials Vanderbilt-Ingram Cancer Center

Dr. Rini is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rini's full profile

Already have an account?

  • Office

    Vanderbilt Division of Hematology & Oncology
    2220 Pierce Ave
    Nashville, TN 37232
    Phone(615) 936-8422
  • Is this information wrong?

Summary

  • Dr. Brian Rini is an oncologist in Nashville, TN and is affiliated with Vanderbilt University Medical Center. He received his medical degree from Ohio State University College of Medicine and has been in practice 22 years. He specializes in genitourinary oncology and hematologic oncology and is experienced in neuro-oncology, amyloidosis, hematologic oncology, breast cancer, and renal cell carcinoma.

Education & Training

  • University of Chicago Medical Center
    University of Chicago Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
  • University of Chicago Medical Center
    University of Chicago Medical CenterResidency, Internal Medicine, 1995 - 1998
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 1995
  • The University of Notre Dame
    The University of Notre DameBA, 1987 - 1991

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 2020 - 2020
  • TN State Medical License
    TN State Medical License 2019 - 2023
  • OH State Medical License
    OH State Medical License 2005 - 2021
  • CA State Medical License
    CA State Medical License 2001 - Present
  • IL State Medical License
    IL State Medical License 1995 - 2002
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Professional Excellence 2011
  • Outstanding Mentor ASCO/AACR Workshop on Methods, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...  
    Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
  • The Association Between Facility Case Volume and Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Targeted Therapy Era  
    Timothy Gilligan, Jorge A Garcia, Brian I Rini, Urologic Oncology
  • Treatment Selection for Men with Metastatic Prostate Cancer Who Progress on Upfront Chemo‐Hormonal Therapy  
    Vadim Koshkin, Prateek Mendiratta, Brian I Rini, Pedro Barata, Christos Kyriakopoulos, Hamid Emamekhoo, Timothy Gilligan, The Prostate
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma.
    Rini BI, Halabi S, Rosenberg JE, Genitourinary Cancer Symposium, abstract 350
  • Metastatic renal cell carcinoma (mRCC) with sarcomatoid component treated with VEGF-targeted therapy.
    Bukowski RM, Garcia JA, Rini BI, Genitourinary Cancer Symposium, abstract 348
  • A prospective trial of Sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab.
    Rini BI, Hutson TE, Elson P, Garcia JA, Genitourinary Cancers Symposium, abstract 346
  • Join now to see all

Lectures

  • Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediat... 
    2019 ASCO Annual Meeting - 6/1/2019
  • A Phase III Trial of Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Metastatic Renal Cell Carcinoma. 
    Genitourinary Cancer Symposium, Oral Presentation
  • Join now to see all

Other

  • Kidney cancer: Does hypothyroidism predict clinical outcome? 
    Rini B, Nat Rev Urol. 2011 Jan;8(1):10-1. PMID: 21116300
  • Editorial comment. 
    Rini BI, Shah SN, Urology. 2010 May;75(5):1114-5
  • Editorial Comment. 
    Campbell SC, Rini BI, J Urol. 182(6):2599-600
  • Join now to see all

Press Mentions

  • Rini Stresses Axitinib Remains Significant in RCC
    Rini Stresses Axitinib Remains Significant in RCCJanuary 20th, 2017
  • Rini Discusses Pembrolizumab/Axitinib, Other Emerging Combos in RCC
    Rini Discusses Pembrolizumab/Axitinib, Other Emerging Combos in RCCJuly 25th, 2017
  • FDA Panel Rejects Immunotherapy MCNA in Bladder Cancer
    FDA Panel Rejects Immunotherapy MCNA in Bladder CancerNovember 18th, 2015
  • Join now to see all

Grant Support

  • Therapeutic Modulation Of Cox-2-Induced Immunosuppression In Metastatic RCCNational Cancer Institute2007–2008

Professional Memberships

Hospital Affiliations